Saatchi shop rebrands to sharpen specialty focus

Share this article:
Saatchi shop rebrands to sharpen specialty focus
Saatchi shop rebrands to sharpen specialty focus
Saatchi & Saatchi Innovations, Publicis' Pennsylvania-based outpost servicing specialty pharma, is rebranding as Saatchi Science.

The Yardley, PA-based shop is looking to sharpen its brand with the name change.

“It's really a reflection of our “Go Forward” business strategy,” said managing director Annemarie Armstrong. “We're narrowing our focus to broaden our appeal to very specific clients in high science and highly complex categories, like oncology, molecular diagnostics and immunology and vaccines. We wanted an identity that reflects that.”

In addition to the new name, the 65-person shop is investing in analytics capability for oncology. Saatchi Science clients include: Pfizer, for which the firm works on Torisel; AstraZeneca, for Caprelsa and Faslodex; and Sanofi Pasteur, for the vaccines portfolio (both adult and pediatric).

“We're building from our strengths,” said Armstrong. “We believe these are categories, particularly oncology and molecular diagnostics in the era of personalized medicine, are very different than [small molecule therapies], so we're investing in the right mix of marketing strategy, scientific understanding, customer insights and creative communications so that we're focusing all of our resources to deliver for these clients.”

Armstrong was named managing director of the shop in July, having previously served in that role on an interim basis. Previously based in Newton, PA, the agency moved in with Publicis Healthcare Communications Group siblings Publicis Touchpoint Solutions and Publicis HealthWare International last year.

The Saatchi healthcare franchise also includes New York-based Saatchi Wellness, specializing in consumer and patient communications, and Saatchi & Saatchi Health Communications, the network's mainline professional-focused arm. 

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.